First European study of Tresiba® shows improved blood glucose control and reduced hypoglycaemia risk

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

Source: Pharmacy Europe - March 11, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News UK Conference and Symposia Diabetes Endochrine Disorders Conference reports Patient care blood glucose control clinical practice hypoglycaemia insulin degludec Source Type: news